tradingkey.logo

Rezolve-Ad Phase 2B Study Of Rezpegaldesleukin Meets Primary And Key Secondary Endpoints In Patients With Moderate-To-Severe Atopic Dermatitis

ReutersJun 24, 2025 11:37 AM

- Nektar Therapeutics NKTR.O:

  • REZOLVE-AD PHASE 2B STUDY OF REZPEGALDESLEUKIN MEETS PRIMARY AND KEY SECONDARY ENDPOINTS IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS

  • NEKTAR THERAPEUTICS - REZOLVE-AD PHASE 2B STUDY MEETS PRIMARY AND KEY SECONDARY ENDPOINTS

  • NEKTAR THERAPEUTICS - ACHIEVED STATISTICAL SIGNIFICANCE ON PRIMARY ENDPOINT AT WEEK 16

  • NEKTAR THERAPEUTICS - SAFETY PROFILE CONSISTENT WITH PREVIOUSLY REPORTED RESULTS

  • NEKTAR THERAPEUTICS: DATA EXPECTED IN Q1 2026 FROM TREATMENT OF PATIENTS WITH ATOPIC DERMATITIS IN LONG-TERM MAINTENANCE PART OF REZOLVE-AD STUDY

  • NEKTAR THERAPEUTICS -TOP-LINE PHASE 2B DATA FOR REZPEGALDESLEUKIN IN ALOPECIA AREATA EXPECTED IN Q4 2025

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI